Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27564097)

  • 1. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy.
    Valdez BC; Li Y; Murray D; Brammer JE; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Oncotarget; 2016 Sep; 7(39):63829-63838. PubMed ID: 27564097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of sodium butyrate on ABC transporters in lung cancer A549 and colorectal cancer HCT116 cells.
    Shi B; Xu FF; Xiang CP; Jia R; Yan CH; Ma SQ; Wang N; Wang AJ; Fan P
    Oncol Lett; 2020 Nov; 20(5):148. PubMed ID: 32934716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
    Bodo J; Sedlak J; Maciejewski JP; Almasan A; Hsi ED
    Apoptosis; 2011 Sep; 16(9):914-23. PubMed ID: 21667043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization.
    Kim H; Kim SN; Park YS; Kim NH; Han JW; Lee HY; Kim YK
    Int J Oncol; 2011 Mar; 38(3):807-12. PubMed ID: 21170509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
    Shimizu R; Kikuchi J; Wada T; Ozawa K; Kano Y; Furukawa Y
    Leukemia; 2010 Oct; 24(10):1760-8. PubMed ID: 20686505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of histone deacetylase inhibitors and the effect on ATP-binding cassette in ovarian carcinoma cells.
    Chao KC; Chang CC; Yen MS; Wang PH
    Eur J Gynaecol Oncol; 2010; 31(4):402-10. PubMed ID: 20882882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
    Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
    Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer.
    Björkman M; Iljin K; Halonen P; Sara H; Kaivanto E; Nees M; Kallioniemi OP
    Int J Cancer; 2008 Dec; 123(12):2774-81. PubMed ID: 18798265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
    Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
    Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).
    Robey RW; Zhan Z; Piekarz RL; Kayastha GL; Fojo T; Bates SE
    Clin Cancer Res; 2006 Mar; 12(5):1547-55. PubMed ID: 16533780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities.
    Dedes KJ; Dedes I; Imesch P; von Bueren AO; Fink D; Fedier A
    Anticancer Drugs; 2009 Jun; 20(5):321-33. PubMed ID: 19322073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
    Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
    J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased MDR1 Transporter Expression in Human Brain Endothelial Cells Through Enhanced Histone Acetylation and Activation of Aryl Hydrocarbon Receptor Signaling.
    You D; Wen X; Gorczyca L; Morris A; Richardson JR; Aleksunes LM
    Mol Neurobiol; 2019 Oct; 56(10):6986-7002. PubMed ID: 30963442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
    Duvic M; Dimopoulos M
    Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.